Last reviewed · How we verify
Ex-9 infusion
At a glance
| Generic name | Ex-9 infusion |
|---|---|
| Sponsor | David D'Alessio, M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Regulation of Insulin Secretion by the GLP-1 Receptor (PHASE4)
- Incretin Action in Physiology and Diabetes (PHASE1)
- DPP4 Inhibition & Beta Cell Function (PHASE1)
- Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines (NA)
- Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4) (NA)
- Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (NA)
- Ghrelin Effect on Beta Cell Function in Health and Disease (NA)
- Effect of GLP-1 on Postprandial Lipid Metabolism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ex-9 infusion CI brief — competitive landscape report
- Ex-9 infusion updates RSS · CI watch RSS
- David D'Alessio, M.D. portfolio CI